The 52-week extension finding that defines the pharmacology as reversible, and what it implies

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Both phase 3 trials had a second 26-week phase in which participants who had received tesamorelin were re-randomised to continue or to switch to placebo. Those who switched regained the visceral fat they had lost, with measurements returning to approximately baseline by week 52, while those who continued held their reduction and gained slightly more. Falutz and colleagues reported this in 2010 and in a pooled analysis. The finding means the effect is a pharmacological state maintained by the drug rather than a durable change, and the label states that fat returns on discontinuation. The same reversibility is seen with growth hormone and with the GLP-1 agonists.

The design

Re-randomisation after the primary endpoint is the standard way to test durability. Participants and investigators remained blinded. Visceral fat was measured by computed tomography at a single abdominal level at baseline, 26 and 52 weeks. The regain curve in the switch group mirrored the loss curve in the first phase.

IGF-1 also returned to baseline in the switch group, confirming the pharmacological withdrawal.

What reversibility implies

The drug changes the growth hormone environment and the fat responds; remove the drug and the environment reverts. There is no remodelling that persists. This places tesamorelin among treatments that manage a state rather than correct it, which is also true of most metabolic drugs. For a regulator it meant the label must say so; for the field it meant that any benefit depends on continued exposure, with the costs and risks that entails.

The parallel with the weight regain after stopping semaglutide, documented in the STEP extension trials, is close.

Why it is here

Because the durability question is one a reader of any body-composition trial should ask, and for tesamorelin it was asked and answered. It describes a trial finding and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The design?

Re-randomisation after the primary endpoint is the standard way to test durability. Participants and investigators remained blinded. Visceral fat was measured by computed tomography at a single abdominal level at baseline, 26 and 52 weeks. The regain curve in the switch group mirrored the loss curve in the first phase.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.